Home » Newsletters » BioWorld

BioWorld

Oct. 1, 2007

View Archived Issues

Stock Winners and Losers For The Week

U.S. Public Offering Performance By Underwriter: January 1 August 31, 2007*

ALL OFFERINGS, ALL UNDERWRITERS, RANKED BY AFTER-MARKET PERFORMANCE*

UNDERWRITERS' PERFORMANCE ON IPOS: FULL CREDIT TO LEAD UNDERWRITER, RANKED BY AFTER-MARKET PERFORMANCE

IPOS: FULL CREDIT TO ALL UNDERWRITERS, RANKED BY GROSS PROCEEDS*

IPOS: FULL CREDIT TO ALL UNDERWRITERS,RANKED BY AFTER-MARKET PERFORMANCE*

PERFORMANCE ON ALL PUBLIC OFFERINGS: FULL CREDIT TO ALL UNDERWRITERS, RANKED BY GROSS PROCEEDS*

PERFORMANCE ON ALL PUBLIC OFFERINGS: FULL CREDIT TO ALL UNDERWRITERS, RANKED BY AFTER-MARKET PERFORMANCE

Quest For New Sleep Drugs Bearing Fruit, Inspiring Deals

Money Raised By Month

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...